Search

Your search keyword '"Gillison, M."' showing total 224 results
Start Over Author "Gillison, M."
224 results on '"Gillison, M."'

1. First-line ADP-A2M4CD8 T-cell Receptor T-cell Therapy plus Pembrolizumab in Head and Neck Cancers: An Additional Cohort of the Phase 1 SURPASS Trial

Author

Ho, A., primary, Garcia-Consuegra, A., additional, Saro, J., additional, Sauer, A., additional, Cristiani, S., additional, Brophy, F.E., additional, Streets, S., additional, Norry, E., additional, Gillison, M., additional, Charlson, J., additional, Bover, M., additional, Zugazagoitia, J., additional, Calvo, E., additional, Ugidos, L., additional, Bruixola, G., additional, Garcia, V. Moreno, additional, Hong, D.S., additional, Rubio-Pérez, J., additional, and Aggen, D.H., additional

Published
2024
Full Text
View/download PDF

2. Surrogate Endpoints in p16-Positive Squamous Cell Carcinoma of the Oropharynx

Author

Gharzai, L.A., primary, Morris, E., additional, Nguyen-Tan, P.F., additional, Rosenthal, D.I., additional, Gillison, M., additional, Harari, P.M., additional, Garden, A.S., additional, Zanotti, K., additional, Caudell, J.J., additional, Jones, C.U., additional, Mitchell, D.L., additional, Krempl, G.A., additional, Ridge, J.A., additional, Gensheimer, M.F., additional, Bonner, J.A., additional, Le, Q.T., additional, Torres-Saavedra, P., additional, Mierzwa, M.L., additional, and Schipper, M., additional

Published
2024
Full Text
View/download PDF

3. Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE consortium

Author

Goyal, N, Hennessy, M, Lehman, E, Lin, W, Agudo, A, Ahrens, W, Boccia, S, Brennan, P, Brenner, H, Cadoni, G, Canova, C, Chen, C, Conway, D, Curado, M, Dal Maso, L, Daudt, A, Edefonti, V, Fabianova, E, Fernandez, L, Franceschi, S, Garavello, W, Gillison, M, Hayes, R, Healy, C, Herrero, R, Holcatova, I, Kanda, J, Kelsey, K, Hansen, B, Koifman, R, Lagiou, P, La Vecchia, C, Levi, F, Li, G, Lissowska, J, Mendoza Lopez, R, Luce, D, Macfarlane, G, Mates, D, Matsuo, K, Mcclean, M, Menezes, A, Menvielle, G, Morgenstern, H, Moysich, K, Negri, E, Olshan, A, Pandics, T, Polesel, J, Purdue, M, Radoi, L, Ramroth, H, Richiardi, L, Schantz, S, Schwartz, S, Serraino, D, Shangina, O, Smith, E, Sturgis, E, Swiatkowska, B, Thomson, P, Vaughan, T, Vilensky, M, Winn, D, Wunsch-Filho, V, Yu, G, Zevallos, J, Zhang, Z, Zheng, T, Znaor, A, Boffetta, P, Hashibe, M, Lee, Y, Muscat, J, Goyal N., Hennessy M., Lehman E., Lin W., Agudo A., Ahrens W., Boccia S., Brennan P., Brenner H., Cadoni G., Canova C., Chen C., Conway D., Curado M., Dal Maso L., Daudt A. W., Edefonti V., Fabianova E., Fernandez L., Franceschi S., Garavello W., Gillison M., Hayes R. B., Healy C., Herrero R., Holcatova I., Kanda J. L., Kelsey K., Hansen B., Koifman R., Lagiou P., La Vecchia C., Levi F., Li G., Lissowska J., Mendoza Lopez R., Luce D., Macfarlane G., Mates D., Matsuo K., McClean M., Menezes A., Menvielle G., Morgenstern H., Moysich K., Negri E., Olshan A. F., Pandics T., Polesel J., Purdue M., Radoi L., Ramroth H., Richiardi L., Schantz S., Schwartz S. M., Serraino D., Shangina O., Smith E., Sturgis E. M., Swiatkowska B., Thomson P., Vaughan T. L., Vilensky M., Winn D. M., Wunsch-Filho V., Yu G. -P., Zevallos J. P., Zhang Z. -F., Zheng T., Znaor A., Boffetta P., Hashibe M., Lee Y. -C. A., Muscat J. E., Goyal, N, Hennessy, M, Lehman, E, Lin, W, Agudo, A, Ahrens, W, Boccia, S, Brennan, P, Brenner, H, Cadoni, G, Canova, C, Chen, C, Conway, D, Curado, M, Dal Maso, L, Daudt, A, Edefonti, V, Fabianova, E, Fernandez, L, Franceschi, S, Garavello, W, Gillison, M, Hayes, R, Healy, C, Herrero, R, Holcatova, I, Kanda, J, Kelsey, K, Hansen, B, Koifman, R, Lagiou, P, La Vecchia, C, Levi, F, Li, G, Lissowska, J, Mendoza Lopez, R, Luce, D, Macfarlane, G, Mates, D, Matsuo, K, Mcclean, M, Menezes, A, Menvielle, G, Morgenstern, H, Moysich, K, Negri, E, Olshan, A, Pandics, T, Polesel, J, Purdue, M, Radoi, L, Ramroth, H, Richiardi, L, Schantz, S, Schwartz, S, Serraino, D, Shangina, O, Smith, E, Sturgis, E, Swiatkowska, B, Thomson, P, Vaughan, T, Vilensky, M, Winn, D, Wunsch-Filho, V, Yu, G, Zevallos, J, Zhang, Z, Zheng, T, Znaor, A, Boffetta, P, Hashibe, M, Lee, Y, Muscat, J, Goyal N., Hennessy M., Lehman E., Lin W., Agudo A., Ahrens W., Boccia S., Brennan P., Brenner H., Cadoni G., Canova C., Chen C., Conway D., Curado M., Dal Maso L., Daudt A. W., Edefonti V., Fabianova E., Fernandez L., Franceschi S., Garavello W., Gillison M., Hayes R. B., Healy C., Herrero R., Holcatova I., Kanda J. L., Kelsey K., Hansen B., Koifman R., Lagiou P., La Vecchia C., Levi F., Li G., Lissowska J., Mendoza Lopez R., Luce D., Macfarlane G., Mates D., Matsuo K., McClean M., Menezes A., Menvielle G., Morgenstern H., Moysich K., Negri E., Olshan A. F., Pandics T., Polesel J., Purdue M., Radoi L., Ramroth H., Richiardi L., Schantz S., Schwartz S. M., Serraino D., Shangina O., Smith E., Sturgis E. M., Swiatkowska B., Thomson P., Vaughan T. L., Vilensky M., Winn D. M., Wunsch-Filho V., Yu G. -P., Zevallos J. P., Zhang Z. -F., Zheng T., Znaor A., Boffetta P., Hashibe M., Lee Y. -C. A., and Muscat J. E.

Abstract

Objective: We analyzed the pooled case-control data from the International Head and Neck Cancer Epidemiology (INHANCE) consortium to compare cigarette smoking and alcohol consumption risk factors for head and neck cancer between less developed and more developed countries. Subjects and Methods: The location of each study was categorized as either a less developed or more developed country. We compared the risk of overall head and neck cancer and cancer of specific anatomic subsites associated with cigarette smoking and alcohol consumption. Additionally, age and sex distribution between categories was compared. Results: The odds ratios for head and neck cancer sites associated with smoking duration differed between less developed and more developed countries. Smoking greater than 20 years conferred a higher risk for oral cavity and laryngeal cancer in more developed countries, whereas the risk was greater for oropharynx and hypopharynx cancer in less developed countries. Alcohol consumed for more than 20 years conferred a higher risk for oropharynx, hypopharynx, and larynx cancer in less developed countries. The proportion of cases that were young (<45 years) or female differed by country type for some HNC subsites. Conclusion: These findings suggest the degree of industrialization and economic development affects the relationship between smoking and alcohol with head and neck cancer.

Published
2023

4. The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer in NRG/RTOG 1016

Author

Weidhaas, J.B., primary, Harris, J., additional, Gillison, M., additional, Blakaj, D.M., additional, Krempl, G.A., additional, Higgins, K.A., additional, Phan, J., additional, Dunlap, N.E., additional, Mahmood, S., additional, Dorth, J.A., additional, Caudell, J.J., additional, Desai, A.B., additional, Galloway, T.J., additional, Pennington, J.D.D., additional, Zhou, Z., additional, Lathrop, J., additional, Torres-Saavedra, P., additional, Hayes, D.N., additional, Yom, S.S., additional, and Le, Q.T., additional

Published
2023
Full Text
View/download PDF

6. Hearing Outcomes in Cisplatin or Cetuximab Combined with Radiation for Patients with HPV-Associated Oropharyngeal Cancer in NRG/RTOG 1016

Author

Runge, C.L., primary, Lyness, J., additional, Gillison, M., additional, Adelstein, D.J., additional, Harari, P.M., additional, Ringash, J.G., additional, Geiger, J.L., additional, Krempl, G.A., additional, Blakaj, D., additional, Bates, J., additional, Galloway, T.J., additional, Jones, C.U., additional, Gensheimer, M., additional, Dunlap, N.E., additional, Phan, J., additional, Caudell, J., additional, Pennington, D., additional, Torres-Saavedra, P., additional, Yom, S.S., additional, Le, Q.T., additional, and Movsas, B., additional

Published
2023
Full Text
View/download PDF

7. HPV Circulating Cell-Free DNA Kinetics in Cervical Cancer Patients Undergoing Definitive Chemoradiation

Author

Seo, A., primary, Xiao, W., additional, Gjyshi, O., additional, Court, K., additional, Napravnik, T. Cisneros, additional, Venkatesan, A., additional, Lynn, E.J., additional, Sammouri, J., additional, Colbert, L., additional, Jhingran, A., additional, Joyner, M.M., additional, Lin, L.L., additional, Gillison, M., additional, and Klopp, A.H., additional

Published
2023
Full Text
View/download PDF

8. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

Author

Psyrri, A., Fayette, J., Harrington, K., Gillison, M., Ahn, M.-J., Takahashi, S., Weiss, J., Machiels, J.-P., Baxi, S., Vasilyev, A., Karpenko, A., Dvorkin, M., Hsieh, C.-Y., Thungappa, S.C., Segura, P.P., Vynnychenko, I., Haddad, R., Kasper, Stefan, Mauz, P.-S., Baker, V., He, P., Evans, B., Wildsmith, S., Olsson, R.F., Yovine, A., Kurland, J.F., Morsli, N., Seiwert, T.Y., UCL - (SLuc) Service d'oncologie médicale, and UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie

Subjects
Oncology, Medizin, Hematology
Abstract

Background: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis. The phase III KESTREL study evaluated the efficacy of durvalumab [programmed death-ligand 1 (PD-L1) antibody] with or without tremelimumab [cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody], versus the EXTREME regimen in patients with R/M HNSCC. Patients and methods: Patients with HNSCC who had not received prior systemic treatment for R/M disease were randomized (2: 1: 1) to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W (up to four doses), durvalumab monotherapy 1500 mg Q4W, or the EXTREME regimen (platinum, 5-fluorouracil, and cetuximab) until disease progression. Durvalumab efficacy, with or without tremelimumab, versus the EXTREME regimen in patients with PD-L1-high tumors and in all randomized patients was assessed. Safety was also assessed. Results: Durvalumab and durvalumab plus tremelimumab were not superior to EXTREME for overall survival (OS) in patients with PD-L1-high expression [median, 10.9 and 11.2 versus 10.9 months, respectively; hazard ratio (HR) = 0.96; 95% confidence interval (CI) 0.69-1.32; P = 0.787 and HR = 1.05; 95% CI 0.80-1.39, respectively]. Durvalumab and durvalumab plus tremelimumab prolonged duration of response versus EXTREME (49.3% and 48.1% versus 9.8% of patients remaining in response at 12 months), correlating with long-term OS for responding patients; however, median progression-free survival was longer with EXTREME (2.8 and 2.8 versus 5.4 months). Exploratory analyses suggested that subsequent immunotherapy use by 24.3% of patients in the EXTREME regimen arm contributed to the similar OS outcomes between arms. Grade 3/4 treatment-related adverse events (TRAEs) for durvalumab, durvalumab plus tremelimumab, and EXTREME were 8.9%, 19.1%, and 53.1%, respectively. Conclusions: In patients with PD-L1-high expression, OS was comparable between durvalumab and the EXTREME regimen. Durvalumab alone, and with tremelimumab, demonstrated durable responses and reduced TRAEs versus the EXTREME regimen in R/M HNSCC.

Published
2023

9. Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE consortium

Author

Goyal, N., Hennessy, M., Lehman, E., Lin, W., Agudo, A., Ahrens, W., Boccia, Stefania, Brennan, P., Brenner, H., Cadoni, Gabriella, Canova, C., Chen, Chen, Conway, D., Curado, M., Dal Maso, L., Daudt, A. W., Edefonti, V., Fabianova, E., Fernandez, L., Franceschi, S., Garavello, W., Gillison, M., Hayes, R. B., Healy, C., Herrero, R., Holcatova, I., Kanda, J. L., Kelsey, K., Hansen, B., Koifman, R., Lagiou, Pagona, La Vecchia, C., Levi, F., Li, G., Lissowska, J., Mendoza Lopez, R., Luce, D., Macfarlane, G., Mates, D., Matsuo, K., Mcclean, M., Menezes, A., Menvielle, G., Morgenstern, H., Moysich, K., Negri, Erica, Olshan, A. F., Pandics, T., Polesel, J., Purdue, M., Radoi, L., Ramroth, H., Richiardi, L., Schantz, S., Schwartz, S. M., Serraino, D., Shangina, O., Smith, E., Sturgis, E. M., Swiatkowska, B., Thomson, P., Vaughan, T. L., Vilensky, M., Winn, D. M., Wunsch-Filho, V., Yu, G. -P., Zevallos, J. P., Zhang, Z. -F., Zheng, T., Znaor, A., Boffetta, Paolo, Hashibe, M., Lee, Y. -C. A., Muscat, J. E., Boccia S. (ORCID:0000-0002-1864-749X), Cadoni G. (ORCID:0000-0001-8244-784X), Chen C., Lagiou P., Negri E., Boffetta P., Goyal, N., Hennessy, M., Lehman, E., Lin, W., Agudo, A., Ahrens, W., Boccia, Stefania, Brennan, P., Brenner, H., Cadoni, Gabriella, Canova, C., Chen, Chen, Conway, D., Curado, M., Dal Maso, L., Daudt, A. W., Edefonti, V., Fabianova, E., Fernandez, L., Franceschi, S., Garavello, W., Gillison, M., Hayes, R. B., Healy, C., Herrero, R., Holcatova, I., Kanda, J. L., Kelsey, K., Hansen, B., Koifman, R., Lagiou, Pagona, La Vecchia, C., Levi, F., Li, G., Lissowska, J., Mendoza Lopez, R., Luce, D., Macfarlane, G., Mates, D., Matsuo, K., Mcclean, M., Menezes, A., Menvielle, G., Morgenstern, H., Moysich, K., Negri, Erica, Olshan, A. F., Pandics, T., Polesel, J., Purdue, M., Radoi, L., Ramroth, H., Richiardi, L., Schantz, S., Schwartz, S. M., Serraino, D., Shangina, O., Smith, E., Sturgis, E. M., Swiatkowska, B., Thomson, P., Vaughan, T. L., Vilensky, M., Winn, D. M., Wunsch-Filho, V., Yu, G. -P., Zevallos, J. P., Zhang, Z. -F., Zheng, T., Znaor, A., Boffetta, Paolo, Hashibe, M., Lee, Y. -C. A., Muscat, J. E., Boccia S. (ORCID:0000-0002-1864-749X), Cadoni G. (ORCID:0000-0001-8244-784X), Chen C., Lagiou P., Negri E., and Boffetta P.

Abstract

Objective We analyzed the pooled case-control data from the International Head and Neck Cancer Epidemiology (INHANCE) consortium to compare cigarette smoking and alcohol consumption risk factors for head and neck cancer between less developed and more developed countries. Subjects and Methods The location of each study was categorized as either a less developed or more developed country. We compared the risk of overall head and neck cancer and cancer of specific anatomic subsites associated with cigarette smoking and alcohol consumption. Additionally, age and sex distribution between categories was compared. Results The odds ratios for head and neck cancer sites associated with smoking duration differed between less developed and more developed countries. Smoking greater than 20 years conferred a higher risk for oral cavity and laryngeal cancer in more developed countries, whereas the risk was greater for oropharynx and hypopharynx cancer in less developed countries. Alcohol consumed for more than 20 years conferred a higher risk for oropharynx, hypopharynx, and larynx cancer in less developed countries. The proportion of cases that were young (<45 years) or female differed by country type for some HNC subsites. Conclusion These findings suggest the degree of industrialization and economic development affects the relationship between smoking and alcohol with head and neck cancer.

Published
2023

10. 943TiP Petosemtamab compared with investigator's choice monotherapy in previously treated patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial.

Author

Haddad, R., Gillison, M., Harrington, K.J., Kim, S-B., Le Tourneau, C., Rosenberg, A., Ford, J., Shen, Y-M., Yao, D., Zohren, F., and Machiels, J-P.

Subjects
*CLINICAL trials, *SQUAMOUS cell carcinoma, *NECK, *METASTASIS, *HEAD
Published
2024
Full Text
View/download PDF

11. Gastrostomy Tube Use in Head and Neck Cancer Survivors, Pre-Treatment Factors Supersede Treatment Intensification: A Second Analysis of RTOG 0129, RTOG 0522, and NRG/RTOG 1016

Author

Galloway, T.J., primary, DeMora, L., additional, Ridge, J.A., additional, Nguyen-Tan, P.F., additional, Rosenthal, D.I., additional, Gillison, M., additional, Garden, A.S., additional, Dunlap, N.E., additional, Caudell, J.J., additional, Jones, C.U., additional, Bauman, J.R., additional, Bahig, H., additional, Shenouda, G., additional, Currey, A.D., additional, Koyfman, S.A., additional, Stokes, W.A., additional, Read, N.E., additional, Pugh, S., additional, and Le, Q.T., additional

Published
2022
Full Text
View/download PDF

15. Lessons learned from the INHANCE consortium: An overview of recent results on head and neck cancer

Author

Bravi, F, Lee, Y, Hashibe, M, Boffetta, P, Conway, D, Ferraroni, M, La Vecchia, C, Edefonti, V, Agudo, A, Ahrens, W, Benhamou, S, Boccia, S, Brennan, P, Brenner, H, Cadoni, G, Canova, C, Chen, C, Chuang, S, Curado, M, Dal Maso, L, Daudt, A, D'Souza, G, Fabianova, E, Fernandez, L, Franceschi, S, Garavello, W, Gillison, M, Gross, N, Hayes, R, Healy, C, Herrero, R, Holcatova, I, Kelsey, K, Kjaerheim, K, Koifman, R, Lagiou, P, Lazarus, P, Levi, F, Li, G, Lissowska, J, Luce, D, Macfarlane, G, Mates, D, Matsuo, K, Mcclean, M, Menezes, A, Menvielle, G, Morgenstern, H, Moyses, R, Moysich, K, Muscat, J, Negri, E, Olshan, A, Pandics, T, Polesel, J, Purdue, M, Radoi, L, Ramroth, H, Richiardi, L, Schantz, S, Schwartz, S, Serraino, D, Shangina, O, Smith, E, Sturgis, E, Swiatkowska, B, Thomson, P, Toporcov, T, Vaughan, T, Vilensky, M, Winn, D, Wunsch-Filho, V, Yu, G, Zevallos, J, Zhang, Z, Zheng, T, Znaor, A, Bravi F., Lee Y. -C. A., Hashibe M., Boffetta P., Conway D. I., Ferraroni M., La Vecchia C., Edefonti V., Agudo A., Ahrens W., Benhamou S., Boccia S., Brennan P., Brenner H., Cadoni G., Canova C., Chen C., Chuang S. -C., Curado M. P., Dal Maso L., Daudt A. W., D'Souza G., Fabianova E., Fernandez L., Franceschi S., Garavello W., Gillison M., Gross N. D., Hayes R. B., Healy C., Herrero R., Holcatova I., Kelsey K., Kjaerheim K., Koifman R., Lagiou P., Lazarus P., Levi F., Li G., Lissowska J., Luce D., Macfarlane G. J., Mates D., Matsuo K., McClean M., Menezes A., Menvielle G., Morgenstern H., Moyses R. A., Moysich K., Muscat J., Negri E., Olshan A. F., Pandics T., Polesel J., Purdue M. P., Radoi L., Ramroth H., Richiardi L., Schantz S., Schwartz S. M., Serraino D., Shangina O., Smith E., Sturgis E. M., Swiatkowska B., Thomson P., Toporcov T. N., Vaughan T. L., Vilensky M., Winn D. M., Wunsch-Filho V., Yu G. -P., Zevallos J. P., Zhang Z. -F., Zheng T., Znaor A., Bravi, F, Lee, Y, Hashibe, M, Boffetta, P, Conway, D, Ferraroni, M, La Vecchia, C, Edefonti, V, Agudo, A, Ahrens, W, Benhamou, S, Boccia, S, Brennan, P, Brenner, H, Cadoni, G, Canova, C, Chen, C, Chuang, S, Curado, M, Dal Maso, L, Daudt, A, D'Souza, G, Fabianova, E, Fernandez, L, Franceschi, S, Garavello, W, Gillison, M, Gross, N, Hayes, R, Healy, C, Herrero, R, Holcatova, I, Kelsey, K, Kjaerheim, K, Koifman, R, Lagiou, P, Lazarus, P, Levi, F, Li, G, Lissowska, J, Luce, D, Macfarlane, G, Mates, D, Matsuo, K, Mcclean, M, Menezes, A, Menvielle, G, Morgenstern, H, Moyses, R, Moysich, K, Muscat, J, Negri, E, Olshan, A, Pandics, T, Polesel, J, Purdue, M, Radoi, L, Ramroth, H, Richiardi, L, Schantz, S, Schwartz, S, Serraino, D, Shangina, O, Smith, E, Sturgis, E, Swiatkowska, B, Thomson, P, Toporcov, T, Vaughan, T, Vilensky, M, Winn, D, Wunsch-Filho, V, Yu, G, Zevallos, J, Zhang, Z, Zheng, T, Znaor, A, Bravi F., Lee Y. -C. A., Hashibe M., Boffetta P., Conway D. I., Ferraroni M., La Vecchia C., Edefonti V., Agudo A., Ahrens W., Benhamou S., Boccia S., Brennan P., Brenner H., Cadoni G., Canova C., Chen C., Chuang S. -C., Curado M. P., Dal Maso L., Daudt A. W., D'Souza G., Fabianova E., Fernandez L., Franceschi S., Garavello W., Gillison M., Gross N. D., Hayes R. B., Healy C., Herrero R., Holcatova I., Kelsey K., Kjaerheim K., Koifman R., Lagiou P., Lazarus P., Levi F., Li G., Lissowska J., Luce D., Macfarlane G. J., Mates D., Matsuo K., McClean M., Menezes A., Menvielle G., Morgenstern H., Moyses R. A., Moysich K., Muscat J., Negri E., Olshan A. F., Pandics T., Polesel J., Purdue M. P., Radoi L., Ramroth H., Richiardi L., Schantz S., Schwartz S. M., Serraino D., Shangina O., Smith E., Sturgis E. M., Swiatkowska B., Thomson P., Toporcov T. N., Vaughan T. L., Vilensky M., Winn D. M., Wunsch-Filho V., Yu G. -P., Zevallos J. P., Zhang Z. -F., Zheng T., and Znaor A.

Abstract

Objective: To summarize the latest evidence on head and neck cancer epidemiology from the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Subjects and Methods: INHANCE was established in 2004 to elucidate the etiology of head and neck cancer through pooled analyses of individual-level data on a large scale. We summarize results from recent INHANCE-based publications updating our 2015 overview. Results: Seventeen papers were published between 2015 and May 2020. These studies further define the nature of risks associated with tobacco and alcohol, and occupational exposures on head and neck cancer. The beneficial effects on incidence of head and neck cancer were identified for good oral health, endogenous and exogenous hormonal factors, and selected aspects of diet related to fruit and vegetables. INHANCE has begun to develop risk prediction models and to pool follow-up data on their studies, finding that ~30% of cases had cancer recurrence and 9% second primary cancers, with overall- and disease-specific 5-year-survival of 51% and 57%, respectively. Conclusions: The number and importance of INHANCE scientific findings provides further evidence of the advantages of large-scale internationally collaborative projects and will support the development of prevention strategies.

Published
2021

16. Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration

Author

Di Credico, G, Polesel, J, Dal Maso, L, Pauli, F, Torelli, N, Luce, D, Radoi, L, Matsuo, K, Serraino, D, Brennan, P, Holcatova, I, Ahrens, W, Lagiou, P, Canova, C, Richiardi, L, Healy, C, Kjaerheim, K, Conway, D, Macfarlane, G, Thomson, P, Agudo, A, Znaor, A, Franceschi, S, Herrero, R, Toporcov, T, Moyses, R, Muscat, J, Negri, E, Vilensky, M, Fernandez, L, Curado, M, Menezes, A, Daudt, A, Koifman, R, Wunsch-Filho, V, Olshan, A, Zevallos, J, Sturgis, E, Li, G, Levi, F, Zhang, Z, Morgenstern, H, Smith, E, Lazarus, P, La Vecchia, C, Garavello, W, Chen, C, Schwartz, S, Zheng, T, Vaughan, T, Kelsey, K, Mcclean, M, Benhamou, S, Hayes, R, Purdue, M, Gillison, M, Schantz, S, Yu, G, Chuang, S, Boffetta, P, Hashibe, M, Yuan-Chin, A, Edefonti, V, Di Credico G., Polesel J., Dal Maso L., Pauli F., Torelli N., Luce D., Radoi L., Matsuo K., Serraino D., Brennan P., Holcatova I., Ahrens W., Lagiou P., Canova C., Richiardi L., Healy C. M., Kjaerheim K., Conway D. I., Macfarlane G. J., Thomson P., Agudo A., Znaor A., Franceschi S., Herrero R., Toporcov T. N., Moyses R. A., Muscat J., Negri E., Vilensky M., Fernandez L., Curado M. P., Menezes A., Daudt A. W., Koifman R., Wunsch-Filho V., Olshan A. F., Zevallos J. P., Sturgis E. M., Li G., Levi F., Zhang Z. -F., Morgenstern H., Smith E., Lazarus P., La Vecchia C., Garavello W., Chen C., Schwartz S. M., Zheng T., Vaughan T. L., Kelsey K., McClean M., Benhamou S., Hayes R. B., Purdue M. P., Gillison M., Schantz S., Yu G. -P., Chuang S. -C., Boffetta P., Hashibe M., Yuan-Chin A. L., Edefonti V., Di Credico, G, Polesel, J, Dal Maso, L, Pauli, F, Torelli, N, Luce, D, Radoi, L, Matsuo, K, Serraino, D, Brennan, P, Holcatova, I, Ahrens, W, Lagiou, P, Canova, C, Richiardi, L, Healy, C, Kjaerheim, K, Conway, D, Macfarlane, G, Thomson, P, Agudo, A, Znaor, A, Franceschi, S, Herrero, R, Toporcov, T, Moyses, R, Muscat, J, Negri, E, Vilensky, M, Fernandez, L, Curado, M, Menezes, A, Daudt, A, Koifman, R, Wunsch-Filho, V, Olshan, A, Zevallos, J, Sturgis, E, Li, G, Levi, F, Zhang, Z, Morgenstern, H, Smith, E, Lazarus, P, La Vecchia, C, Garavello, W, Chen, C, Schwartz, S, Zheng, T, Vaughan, T, Kelsey, K, Mcclean, M, Benhamou, S, Hayes, R, Purdue, M, Gillison, M, Schantz, S, Yu, G, Chuang, S, Boffetta, P, Hashibe, M, Yuan-Chin, A, Edefonti, V, Di Credico G., Polesel J., Dal Maso L., Pauli F., Torelli N., Luce D., Radoi L., Matsuo K., Serraino D., Brennan P., Holcatova I., Ahrens W., Lagiou P., Canova C., Richiardi L., Healy C. M., Kjaerheim K., Conway D. I., Macfarlane G. J., Thomson P., Agudo A., Znaor A., Franceschi S., Herrero R., Toporcov T. N., Moyses R. A., Muscat J., Negri E., Vilensky M., Fernandez L., Curado M. P., Menezes A., Daudt A. W., Koifman R., Wunsch-Filho V., Olshan A. F., Zevallos J. P., Sturgis E. M., Li G., Levi F., Zhang Z. -F., Morgenstern H., Smith E., Lazarus P., La Vecchia C., Garavello W., Chen C., Schwartz S. M., Zheng T., Vaughan T. L., Kelsey K., McClean M., Benhamou S., Hayes R. B., Purdue M. P., Gillison M., Schantz S., Yu G. -P., Chuang S. -C., Boffetta P., Hashibe M., Yuan-Chin A. L., and Edefonti V.

Abstract

Background: Alcohol is a well-established risk factor for head and neck cancer (HNC). This study aims to explore the effect of alcohol intensity and duration, as joint continuous exposures, on HNC risk. Methods: Data from 26 case-control studies in the INHANCE Consortium were used, including never and current drinkers who drunk ≤10 drinks/day for ≤54 years (24234 controls, 4085 oral cavity, 3359 oropharyngeal, 983 hypopharyngeal and 3340 laryngeal cancers). The dose-response relationship between the risk and the joint exposure to drinking intensity and duration was investigated through bivariate regression spline models, adjusting for potential confounders, including tobacco smoking. Results: For all subsites, cancer risk steeply increased with increasing drinks/day, with no appreciable threshold effect at lower intensities. For each intensity level, the risk of oral cavity, hypopharyngeal and laryngeal cancers did not vary according to years of drinking, suggesting no effect of duration. For oropharyngeal cancer, the risk increased with durations up to 28 years, flattening thereafter. The risk peaked at the higher levels of intensity and duration for all subsites (odds ratio = 7.95 for oral cavity, 12.86 for oropharynx, 24.96 for hypopharynx and 6.60 for larynx). Conclusions: Present results further encourage the reduction of alcohol intensity to mitigate HNC risk.

Published
2020

19. A Phase 2/3, Randomized, Open-Label Study of Bempegaldesleukin Plus Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma with PD-L1-Expressing Tumors (PROPEL-36)

Author

Seiwert, T.Y., primary, Haddad, R.I., additional, Johnson, D., additional, Gillison, M., additional, Keilholz, U., additional, Tahara, M., additional, Machiels, J.P., additional, Deeken, J., additional, Villaflor, V., additional, Su, Y., additional, Guthrie, T., additional, Shin, D.M., additional, De Block, K., additional, Meirovitz, A., additional, Chien, D., additional, Tagliaferri, M., additional, Zalvesky, J., additional, and Harrington, K., additional

Published
2022
Full Text
View/download PDF

20. Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE consortium

Author

Goyal, N. Hennessy, M. Lehman, E. Lin, W. Agudo, A. Ahrens, W. Boccia, S. Brennan, P. Brenner, H. Cadoni, G. Canova, C. Chen, C. Conway, D. Curado, M. Dal Maso, L. Daudt, A.W. Edefonti, V. Fabianova, E. Fernandez, L. Franceschi, S. Garavello, W. Gillison, M. Hayes, R.B. Healy, C. Herrero, R. Holcatova, I. Kanda, J.L. Kelsey, K. Hansen, B. Koifman, R. Lagiou, P. La Vecchia, C. Levi, F. Li, G. Lissowska, J. Mendoza López, R. Luce, D. Macfarlane, G. Mates, D. Matsuo, K. McClean, M. Menezes, A. Menvielle, G. Morgenstern, H. Moysich, K. Negri, E. Olshan, A.F. Pandics, T. Polesel, J. Purdue, M. Radoi, L. Ramroth, H. Richiardi, L. Schantz, S. Schwartz, S.M. Serraino, D. Shangina, O. Smith, E. Sturgis, E.M. Świątkowska, B. Thomson, P. Vaughan, T.L. Vilensky, M. Winn, D.M. Wunsch-Filho, V. Yu, G.-P. Zevallos, J.P. Zhang, Z.-F. Zheng, T. Znaor, A. Boffetta, P. Hashibe, M. Lee, Y.-C.A. Muscat, J.E.

Abstract

Objective: We analyzed the pooled case-control data from the International Head and Neck Cancer Epidemiology (INHANCE) consortium to compare cigarette smoking and alcohol consumption risk factors for head and neck cancer between less developed and more developed countries. Subjects and Methods: The location of each study was categorized as either a less developed or more developed country. We compared the risk of overall head and neck cancer and cancer of specific anatomic subsites associated with cigarette smoking and alcohol consumption. Additionally, age and sex distribution between categories was compared. Results: The odds ratios for head and neck cancer sites associated with smoking duration differed between less developed and more developed countries. Smoking greater than 20 years conferred a higher risk for oral cavity and laryngeal cancer in more developed countries, whereas the risk was greater for oropharynx and hypopharynx cancer in less developed countries. Alcohol consumed for more than 20 years conferred a higher risk for oropharynx, hypopharynx, and larynx cancer in less developed countries. The proportion of cases that were young (

Published
2022

21. Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer: A bivariate spline model approach

Author

Di Credico, G, Edefonti, V, Polesel, J, Pauli, F, Torelli, N, Serraino, D, Negri, E, Luce, D, Stucker, I, Matsuo, K, Brennan, P, Vilensky, M, Fernandez, L, Curado, M, Menezes, A, Daudt, A, Koifman, R, Wunsch-Filho, V, Holcatova, I, Ahrens, W, Lagiou, P, Simonato, L, Richiardi, L, Healy, C, Kjaerheim, K, Conway, D, Macfarlane, T, Thomson, P, Agudo, A, Znaor, A, Boaventura Rios, L, Toporcov, T, Franceschi, S, Herrero, R, Muscat, J, Olshan, A, Zevallos, J, La Vecchia, C, Winn, D, Sturgis, E, Li, G, Fabianova, E, Lissowska, J, Mates, D, Rudnai, P, Shangina, O, Swiatkowska, B, Moysich, K, Zhang, Z, Morgenstern, H, Levi, F, Smith, E, Lazarus, P, Bosetti, C, Garavello, W, Kelsey, K, Mcclean, M, Ramroth, H, Chen, C, Schwartz, S, Vaughan, T, Zheng, T, Menvielle, G, Boccia, S, Cadoni, G, Hayes, R, Purdue, M, Gillison, M, Schantz, S, Yu, G, Brenner, H, D'Souza, G, Gross, N, Chuang, S, Boffetta, P, Hashibe, M, Lee, Y, Dal Maso, L, Di Credico G., Edefonti V., Polesel J., Pauli F., Torelli N., Serraino D., Negri E., Luce D., Stucker I., Matsuo K., Brennan P., Vilensky M., Fernandez L., Curado M. P., Menezes A., Daudt A. W., Koifman R., Wunsch-Filho V., Holcatova I., Ahrens W., Lagiou P., Simonato L., Richiardi L., Healy C., Kjaerheim K., Conway D. I., Macfarlane T. V., Thomson P., Agudo A., Znaor A., Boaventura Rios L. F., Toporcov T. N., Franceschi S., Herrero R., Muscat J., Olshan A. F., Zevallos J. P., La Vecchia C., Winn D. M., Sturgis E. M., Li G., Fabianova E., Lissowska J., Mates D., Rudnai P., Shangina O., Swiatkowska B., Moysich K., Zhang Z. -F., Morgenstern H., Levi F., Smith E., Lazarus P., Bosetti C., Garavello W., Kelsey K., McClean M., Ramroth H., Chen C., Schwartz S. M., Vaughan T. L., Zheng T., Menvielle G., Boccia S., Cadoni G., Hayes R. B., Purdue M., Gillison M., Schantz S., Yu G. -P., Brenner H., D'Souza G., Gross N. D., Chuang S. -C., Boffetta P., Hashibe M., Lee Y. -C. A., Dal Maso L., Di Credico, G, Edefonti, V, Polesel, J, Pauli, F, Torelli, N, Serraino, D, Negri, E, Luce, D, Stucker, I, Matsuo, K, Brennan, P, Vilensky, M, Fernandez, L, Curado, M, Menezes, A, Daudt, A, Koifman, R, Wunsch-Filho, V, Holcatova, I, Ahrens, W, Lagiou, P, Simonato, L, Richiardi, L, Healy, C, Kjaerheim, K, Conway, D, Macfarlane, T, Thomson, P, Agudo, A, Znaor, A, Boaventura Rios, L, Toporcov, T, Franceschi, S, Herrero, R, Muscat, J, Olshan, A, Zevallos, J, La Vecchia, C, Winn, D, Sturgis, E, Li, G, Fabianova, E, Lissowska, J, Mates, D, Rudnai, P, Shangina, O, Swiatkowska, B, Moysich, K, Zhang, Z, Morgenstern, H, Levi, F, Smith, E, Lazarus, P, Bosetti, C, Garavello, W, Kelsey, K, Mcclean, M, Ramroth, H, Chen, C, Schwartz, S, Vaughan, T, Zheng, T, Menvielle, G, Boccia, S, Cadoni, G, Hayes, R, Purdue, M, Gillison, M, Schantz, S, Yu, G, Brenner, H, D'Souza, G, Gross, N, Chuang, S, Boffetta, P, Hashibe, M, Lee, Y, Dal Maso, L, Di Credico G., Edefonti V., Polesel J., Pauli F., Torelli N., Serraino D., Negri E., Luce D., Stucker I., Matsuo K., Brennan P., Vilensky M., Fernandez L., Curado M. P., Menezes A., Daudt A. W., Koifman R., Wunsch-Filho V., Holcatova I., Ahrens W., Lagiou P., Simonato L., Richiardi L., Healy C., Kjaerheim K., Conway D. I., Macfarlane T. V., Thomson P., Agudo A., Znaor A., Boaventura Rios L. F., Toporcov T. N., Franceschi S., Herrero R., Muscat J., Olshan A. F., Zevallos J. P., La Vecchia C., Winn D. M., Sturgis E. M., Li G., Fabianova E., Lissowska J., Mates D., Rudnai P., Shangina O., Swiatkowska B., Moysich K., Zhang Z. -F., Morgenstern H., Levi F., Smith E., Lazarus P., Bosetti C., Garavello W., Kelsey K., McClean M., Ramroth H., Chen C., Schwartz S. M., Vaughan T. L., Zheng T., Menvielle G., Boccia S., Cadoni G., Hayes R. B., Purdue M., Gillison M., Schantz S., Yu G. -P., Brenner H., D'Souza G., Gross N. D., Chuang S. -C., Boffetta P., Hashibe M., Lee Y. -C. A., and Dal Maso L.

Abstract

Objectives: This study aimed at re-evaluating the strength and shape of the dose-response relationship between the combined (or joint) effect of intensity and duration of cigarette smoking and the risk of head and neck cancer (HNC). We explored this issue considering bivariate spline models, where smoking intensity and duration were treated as interacting continuous exposures. Materials and Methods: We pooled individual-level data from 33 case-control studies (18,260 HNC cases and 29,844 controls) participating in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. In bivariate regression spline models, exposures to cigarette smoking intensity and duration (compared with never smokers) were modeled as a linear piecewise function within a logistic regression also including potential confounders. We jointly estimated the optimal knot locations and regression parameters within the Bayesian framework. Results: For oral-cavity/pharyngeal (OCP) cancers, an odds ratio (OR) >5 was reached after 30 years in current smokers of ∼20 or more cigarettes/day. Patterns of OCP cancer risk in current smokers differed across strata of alcohol intensity. For laryngeal cancer, ORs >20 were found for current smokers of ≥20 cigarettes/day for ≥30 years. In former smokers who quit ≥10 years ago, the ORs were approximately halved for OCP cancers, and ∼1/3 for laryngeal cancer, as compared to the same levels of intensity and duration in current smokers. Conclusion: Referring to bivariate spline models, this study better quantified the joint effect of intensity and duration of cigarette smoking on HNC risk, further stressing the need of smoking cessation policies

Published
2019

23. 927TiP SKYSCRAPER-09: A phase II, randomised, double-blinded study of atezolizumab (Atezo) + tiragolumab (Tira) and atezo + placebo as first-line (1L) therapy for recurrent/metastatic (R/M) PD-L1+ squamous cell carcinoma of the head and neck (SCCHN)

Author

Cohen, E., primary, Fayette, J., additional, Harrington, K.J., additional, Johnson, M.L., additional, Kao, H-F., additional, Lee, S-H., additional, Licitra, L.F., additional, Ngamphaiboon, N., additional, Psyrri, A., additional, Wong, D.J., additional, Afshari, M., additional, Cvijovic, K., additional, Goodman, G.R., additional, Komatsubara, K.M., additional, Matheny, C., additional, Pham, T.Q., additional, Tang, H., additional, Wang, L., additional, Yan, Y., additional, and Gillison, M., additional

Published
2021
Full Text
View/download PDF

24. LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

Author

Argiris, A., primary, Harrington, K., additional, Tahara, M., additional, Ferris, R.L., additional, Gillison, M., additional, Fayette, J., additional, Daste, A., additional, Koralewski, P., additional, Mesia Nin, R., additional, Saba, N.F., additional, Mak, M., additional, Álvarez Avitia, M.A., additional, Guminski, A., additional, Müller-Richter, U., additional, Kiyota, N., additional, Roberts, M., additional, Khan, T.A., additional, Miller-Moslin, K., additional, Wei, L., additional, and Robert Haddad, R., additional

Published
2021
Full Text
View/download PDF

25. Infection with Human Papilloma Virus (HPV) and risk of subsites within the oral cancer

Author

Giraldi, Luca, Collatuzzo, G., Hashim, D., Franceschi, S., Herrero, R., Chen, Chen, Schwartz, S. M., Smith, E., Kelsey, K., Mcclean, M., Gillison, M., Boccia, Stefania, Hashibe, M., Amy Lee, Y. -C., Boffetta, Paolo, Giraldi L., Chen C., Boccia S. (ORCID:0000-0002-1864-749X), Boffetta P., Giraldi, Luca, Collatuzzo, G., Hashim, D., Franceschi, S., Herrero, R., Chen, Chen, Schwartz, S. M., Smith, E., Kelsey, K., Mcclean, M., Gillison, M., Boccia, Stefania, Hashibe, M., Amy Lee, Y. -C., Boffetta, Paolo, Giraldi L., Chen C., Boccia S. (ORCID:0000-0002-1864-749X), and Boffetta P.

Abstract

Background: The aim of this study was to investigate the relationship between high-risk genotypes of Human Papilloma Virus (HPV) and cancer of different subsites of the oral cavity. Material and methods: A pooled analysis of five studies included on the International Head and Neck Cancer Epidemiology (INHANCE) Consortium was conducted. HPV 16 and HPV 18 were considered. Adjusted odds ratios (ORs) and corresponding 95 % confidence intervals (CIs) for HPV and each oral cavity subsites were simultaneously estimated using multinomial logistic regression models. Results: The analysis included 1157 cases and 3272 controls. This study showed a slightly higher prevalence of HPV infection among oral cancer cases than controls. In particular, an increased risk of other and not otherwise specified (NOS) sites within the oral cavity, oral tongue, palate and floor of mouth cancer was observed for overall HPV16 positivity (OR = 1.66, 95 % CI: 1.01−2.72; OR = 1.97, 95 % CI: 1.36−2.85; OR = 2.48, 95 % CI: 1.50−4.11; OR = 2.71, 95 % CI: 1.06−6.95, respectively). In particular, HPV16E7 was related to cancer of floor of mouth, oral cavity NOS and palate (OR = 2.71, 95 % CI: 1.06−6.95; OR = 3.32, 95 % CI:1.53−7.19; OR = 3.34, 95 % CI:1.38−8.06). Results were inconsistent for HPV18 due to low prevalence of infection. Conclusion: Our study suggests that HPV16 infection may increase the risk of developing floor of mouth, gum, tongue, and palate cancers. Clinical relevance: Subjects with HPV infection have a higher risk of cancer from all sites of the oral cavity.

Published
2021

26. Lessons learned from the INHANCE consortium: An overview of recent results on head and neck cancer

Author

Bravi, F., Lee, Y. -C. A., Hashibe, M., Boffetta, Paolo, Conway, D. I., Ferraroni, M., La Vecchia, C., Edefonti, V., Agudo, A., Ahrens, W., Benhamou, S., Boccia, Stefania, Brennan, P., Brenner, H., Cadoni, Gabriella, Canova, C., Chen, Chen, Chuang, S. -C., Curado, M. P., Dal Maso, L., Daudt, A. W., D'Souza, G., Fabianova, E., Fernandez, L., Franceschi, S., Garavello, W., Gillison, M., Gross, N. D., Hayes, R. B., Healy, C., Herrero, R., Holcatova, I., Kelsey, K., Kjaerheim, K., Koifman, R., Lagiou, Pagona, Lazarus, P., Levi, F., Li, G., Lissowska, J., Luce, D., Macfarlane, G. J., Mates, D., Matsuo, K., Mcclean, M., Menezes, A., Menvielle, G., Morgenstern, H., Moyses, R. A., Moysich, K., Muscat, J., Negri, Erica, Olshan, A. F., Pandics, T., Polesel, J., Purdue, M. P., Radoi, L., Ramroth, H., Richiardi, L., Schantz, S., Schwartz, S. M., Serraino, D., Shangina, O., Smith, E., Sturgis, E. M., Swiatkowska, B., Thomson, P., Toporcov, T. N., Vaughan, T. L., Vilensky, M., Winn, D. M., Wunsch-Filho, V., Yu, G. -P., Zevallos, J. P., Zhang, Z. -F., Zheng, T., Znaor, A., Boffetta P., Boccia S. (ORCID:0000-0002-1864-749X), Cadoni G. (ORCID:0000-0001-8244-784X), Chen C., Lagiou P., Negri E., Bravi, F., Lee, Y. -C. A., Hashibe, M., Boffetta, Paolo, Conway, D. I., Ferraroni, M., La Vecchia, C., Edefonti, V., Agudo, A., Ahrens, W., Benhamou, S., Boccia, Stefania, Brennan, P., Brenner, H., Cadoni, Gabriella, Canova, C., Chen, Chen, Chuang, S. -C., Curado, M. P., Dal Maso, L., Daudt, A. W., D'Souza, G., Fabianova, E., Fernandez, L., Franceschi, S., Garavello, W., Gillison, M., Gross, N. D., Hayes, R. B., Healy, C., Herrero, R., Holcatova, I., Kelsey, K., Kjaerheim, K., Koifman, R., Lagiou, Pagona, Lazarus, P., Levi, F., Li, G., Lissowska, J., Luce, D., Macfarlane, G. J., Mates, D., Matsuo, K., Mcclean, M., Menezes, A., Menvielle, G., Morgenstern, H., Moyses, R. A., Moysich, K., Muscat, J., Negri, Erica, Olshan, A. F., Pandics, T., Polesel, J., Purdue, M. P., Radoi, L., Ramroth, H., Richiardi, L., Schantz, S., Schwartz, S. M., Serraino, D., Shangina, O., Smith, E., Sturgis, E. M., Swiatkowska, B., Thomson, P., Toporcov, T. N., Vaughan, T. L., Vilensky, M., Winn, D. M., Wunsch-Filho, V., Yu, G. -P., Zevallos, J. P., Zhang, Z. -F., Zheng, T., Znaor, A., Boffetta P., Boccia S. (ORCID:0000-0002-1864-749X), Cadoni G. (ORCID:0000-0001-8244-784X), Chen C., Lagiou P., and Negri E.

Abstract

Objective: To summarize the latest evidence on head and neck cancer epidemiology from the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Subjects and Methods: INHANCE was established in 2004 to elucidate the etiology of head and neck cancer through pooled analyses of individual-level data on a large scale. We summarize results from recent INHANCE-based publications updating our 2015 overview. Results: Seventeen papers were published between 2015 and May 2020. These studies further define the nature of risks associated with tobacco and alcohol, and occupational exposures on head and neck cancer. The beneficial effects on incidence of head and neck cancer were identified for good oral health, endogenous and exogenous hormonal factors, and selected aspects of diet related to fruit and vegetables. INHANCE has begun to develop risk prediction models and to pool follow-up data on their studies, finding that ~30% of cases had cancer recurrence and 9% second primary cancers, with overall- and disease-specific 5-year-survival of 51% and 57%, respectively. Conclusions: The number and importance of INHANCE scientific findings provides further evidence of the advantages of large-scale internationally collaborative projects and will support the development of prevention strategies.

Published
2021

28. 857O MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN)

Author

Blanchard, P., Cheugoua-Zanetsie, M., Deneche, I., Rosenthal, D.I., Gillison, M., Eriksen, J.G., Prabhash, K., Giralt, J., Bonner, J.A., Ghi, M.G., Mehanna, H., Siu, L.L., Gebre Medhin, M., Rischin, D., Dietz, A., Mesia Nin, R., Pointreau, Y., Crombet, T., and Auperin, A.

Published
2023
Full Text
View/download PDF

29. De-escalation after DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup framework for future de-escalation studies

Author

Mehanna, H. Rischin, D. Wong, S.J. Gregoire, V. Ferris, R. Waldron, J. Le, Q.-T. Forster, M. Gillison, M. Laskar, S. Tahara, M. Psyrri, A. Vermorken, J. Porceddu, S.

Abstract

Human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) is increasing rapidly. The younger age, significantly improved prognosis, and relative morbidity of the standard-of-care cisplatin and radiotherapy in this population have led to the popularization of the concept of treatment de-escalation. The recent results of the first 3 randomized de-escalation trials, however, have shown a clear detriment in survival when cisplatin is omitted or substituted. In view of these results, the Head and Neck Cancer International Group identified the need to issue guidance regarding future de-escalation studies for patients with HPV-positive head and neck cancer to avoid the possibility of patients being harmed. We review the current state of the literature regarding HPV de-escalation trials and present a framework and guidance on future and existing clinical trials for treatment de-escalation of HPV-positive OPC. De-escalation paradigms of HPV-positive OPC should be evaluated in phase II studies, and results should be awaited before proceeding to phase III studies. Implementation into clinical practice before high-level evidence is available should not be undertaken in this context. Finally, harm-minimization techniques should also be evaluated as an alternative to de-escalation of treatment in these patient groups. © 2020 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License

Published
2020

30. Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration

Author

Di Credico, G. Polesel, J. Dal Maso, L. Pauli, F. Torelli, N. Luce, D. Radoï, L. Matsuo, K. Serraino, D. Brennan, P. Holcatova, I. Ahrens, W. Lagiou, P. Canova, C. Richiardi, L. Healy, C.M. Kjaerheim, K. Conway, D.I. Macfarlane, G.J. Thomson, P. Agudo, A. Znaor, A. Franceschi, S. Herrero, R. Toporcov, T.N. Moyses, R.A. Muscat, J. Negri, E. Vilensky, M. Fernandez, L. Curado, M.P. Menezes, A. Daudt, A.W. Koifman, R. Wunsch-Filho, V. Olshan, A.F. Zevallos, J.P. Sturgis, E.M. Li, G. Levi, F. Zhang, Z.-F. Morgenstern, H. Smith, E. Lazarus, P. La Vecchia, C. Garavello, W. Chen, C. Schwartz, S.M. Zheng, T. Vaughan, T.L. Kelsey, K. McClean, M. Benhamou, S. Hayes, R.B. Purdue, M.P. Gillison, M. Schantz, S. Yu, G.-P. Chuang, S.-C. Boffetta, P. Hashibe, M. Yuan-Chin, A.L. Edefonti, V.

Abstract

Background: Alcohol is a well-established risk factor for head and neck cancer (HNC). This study aims to explore the effect of alcohol intensity and duration, as joint continuous exposures, on HNC risk. Methods: Data from 26 case-control studies in the INHANCE Consortium were used, including never and current drinkers who drunk ≤10 drinks/day for ≤54 years (24234 controls, 4085 oral cavity, 3359 oropharyngeal, 983 hypopharyngeal and 3340 laryngeal cancers). The dose-response relationship between the risk and the joint exposure to drinking intensity and duration was investigated through bivariate regression spline models, adjusting for potential confounders, including tobacco smoking. Results: For all subsites, cancer risk steeply increased with increasing drinks/day, with no appreciable threshold effect at lower intensities. For each intensity level, the risk of oral cavity, hypopharyngeal and laryngeal cancers did not vary according to years of drinking, suggesting no effect of duration. For oropharyngeal cancer, the risk increased with durations up to 28 years, flattening thereafter. The risk peaked at the higher levels of intensity and duration for all subsites (odds ratio = 7.95 for oral cavity, 12.86 for oropharynx, 24.96 for hypopharynx and 6.60 for larynx). Conclusions: Present results further encourage the reduction of alcohol intensity to mitigate HNC risk. © 2020, The Author(s), under exclusive licence to Cancer Research UK.

Published
2020

31. De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies

Author

Mehanna, H, Rischin, D, Wong, SJ, Gregoire, V, Ferris, R, Waldron, J, Le, Q-T, Forster, M, Gillison, M, Laskar, S, Tahara, M, Psyrri, A, Vermorken, J, Porceddu, S, Mehanna, H, Rischin, D, Wong, SJ, Gregoire, V, Ferris, R, Waldron, J, Le, Q-T, Forster, M, Gillison, M, Laskar, S, Tahara, M, Psyrri, A, Vermorken, J, and Porceddu, S

Abstract

Human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) is increasing rapidly. The younger age, significantly improved prognosis, and relative morbidity of the standard-of-care cisplatin and radiotherapy in this population have led to the popularization of the concept of treatment de-escalation. The recent results of the first 3 randomized de-escalation trials, however, have shown a clear detriment in survival when cisplatin is omitted or substituted. In view of these results, the Head and Neck Cancer International Group identified the need to issue guidance regarding future de-escalation studies for patients with HPV-positive head and neck cancer to avoid the possibility of patients being harmed. We review the current state of the literature regarding HPV de-escalation trials and present a framework and guidance on future and existing clinical trials for treatment de-escalation of HPV-positive OPC. De-escalation paradigms of HPV-positive OPC should be evaluated in phase II studies, and results should be awaited before proceeding to phase III studies. Implementation into clinical practice before high-level evidence is available should not be undertaken in this context. Finally, harm-minimization techniques should also be evaluated as an alternative to de-escalation of treatment in these patient groups.

Published
2020

33. 1028P Clinical results of a pilot trial of GEN-009, a neoantigen vaccine containing immunogenic tumour specific neoantigens, in combination with PD-1 inhibitors in advanced cancers

Author

Gillison, M., primary, Awad, M.M., additional, Twardowski, P., additional, Cohen, R.B., additional, Stein, M., additional, Sukari, A., additional, Johnson, M., additional, Lackner, R., additional, DeCillis, A., additional, Hernandez, R., additional, Price, J., additional, Dowal, L., additional, Shainheit, M., additional, DeOliveira, D.B., additional, Jain, M., additional, Lapham, P., additional, Singh, N., additional, Flechtner, J.B., additional, and Davis, T., additional

Published
2020
Full Text
View/download PDF

34. 975TiP Phase Ib trial of ABBV-368 + tilsotolimod in combination with nab-paclitaxel and/or budigalimab (ABBV-181) in patients with recurrent/metastatic head and neck squamous cell carcinoma

Author

Le, X., primary, Gluck, I., additional, Maurice-Dror, C., additional, Panwar, A., additional, Gold, K., additional, Berlin, J., additional, Dai, T., additional, Grewal, J., additional, Nagasaka, M., additional, Rosenberg, A., additional, Haigentz, M., additional, Le Tourneau, C., additional, Moreno, I., additional, McDevitt, M., additional, Patel, M., additional, Da Costa, D., additional, Lambert, S., additional, Li, Y., additional, Blaney, M., additional, and Gillison, M., additional

Published
2020
Full Text
View/download PDF

35. Multi-Institutional Randomized Double-Blind Phase II Trial of Everolimus vs. Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)

Author

Nathan, C.A.O., primary, Hayes, D.N., additional, Harismendy, O., additional, Flores, J., additional, Moore-Medlin, T., additional, Gutkind, J.S., additional, Neupane, P., additional, Mills, G., additional, Sargi, Z.B., additional, Seiwert, T.Y., additional, Grilley-Olson, J., additional, Day, T., additional, Gillison, M., additional, Wade, J., additional, Feldman, L., additional, Jha, G., additional, Kozloff, M., additional, O'Leary, M., additional, Worden, F., additional, and Cohen, E., additional

Published
2020
Full Text
View/download PDF

36. Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer: A bivariate spline model approach

Author

Di Credico, G., Edefonti, V., Polesel, J., Pauli, F., Torelli, N., Serraino, D., Negri, E., Luce, D., Stucker, I., Matsuo, K., Brennan, P., Vilensky, M., Fernandez, L., Curado, M. P., Menezes, A., Daudt, A. W., Koifman, R., Wunsch-Filho, V., Holcatova, I., Ahrens, W., Lagiou, Pagona, Simonato, L., Richiardi, L., Healy, C., Kjaerheim, K., Conway, D. I., Macfarlane, T. V., Thomson, P., Agudo, A., Znaor, A., Boaventura Rios, L. F., Toporcov, T. N., Franceschi, S., Herrero, R., Muscat, J., Olshan, A. F., Zevallos, J. P., La Vecchia, C., Winn, D. M., Sturgis, E. M., Li, G., Fabianova, E., Lissowska, J., Mates, D., Rudnai, P., Shangina, O., Swiatkowska, B., Moysich, K., Zhang, Z. -F., Morgenstern, H., Levi, F., Smith, E., Lazarus, P., Bosetti, C., Garavello, W., Kelsey, K., Mcclean, M., Ramroth, H., Chen, C., Schwartz, S. M., Vaughan, T. L., Zheng, T., Menvielle, G., Boccia, Stefania, Cadoni, Gabriella, Hayes, R. B., Purdue, M., Gillison, M., Schantz, S., Yu, G. -P., Brenner, H., D'Souza, G., Gross, N. D., Chuang, S. -C., Boffetta, Paolo, Hashibe, M., Lee, Y. -C. A., Dal Maso, L., Lagiou P., Boccia S. (ORCID:0000-0002-1864-749X), Cadoni G. (ORCID:0000-0001-8244-784X), Boffetta P., Di Credico, G., Edefonti, V., Polesel, J., Pauli, F., Torelli, N., Serraino, D., Negri, E., Luce, D., Stucker, I., Matsuo, K., Brennan, P., Vilensky, M., Fernandez, L., Curado, M. P., Menezes, A., Daudt, A. W., Koifman, R., Wunsch-Filho, V., Holcatova, I., Ahrens, W., Lagiou, Pagona, Simonato, L., Richiardi, L., Healy, C., Kjaerheim, K., Conway, D. I., Macfarlane, T. V., Thomson, P., Agudo, A., Znaor, A., Boaventura Rios, L. F., Toporcov, T. N., Franceschi, S., Herrero, R., Muscat, J., Olshan, A. F., Zevallos, J. P., La Vecchia, C., Winn, D. M., Sturgis, E. M., Li, G., Fabianova, E., Lissowska, J., Mates, D., Rudnai, P., Shangina, O., Swiatkowska, B., Moysich, K., Zhang, Z. -F., Morgenstern, H., Levi, F., Smith, E., Lazarus, P., Bosetti, C., Garavello, W., Kelsey, K., Mcclean, M., Ramroth, H., Chen, C., Schwartz, S. M., Vaughan, T. L., Zheng, T., Menvielle, G., Boccia, Stefania, Cadoni, Gabriella, Hayes, R. B., Purdue, M., Gillison, M., Schantz, S., Yu, G. -P., Brenner, H., D'Souza, G., Gross, N. D., Chuang, S. -C., Boffetta, Paolo, Hashibe, M., Lee, Y. -C. A., Dal Maso, L., Lagiou P., Boccia S. (ORCID:0000-0002-1864-749X), Cadoni G. (ORCID:0000-0001-8244-784X), and Boffetta P.

Abstract

Objectives: This study aimed at re-evaluating the strength and shape of the dose-response relationship between the combined (or joint) effect of intensity and duration of cigarette smoking and the risk of head and neck cancer (HNC). We explored this issue considering bivariate spline models, where smoking intensity and duration were treated as interacting continuous exposures. Materials and Methods: We pooled individual-level data from 33 case-control studies (18,260 HNC cases and 29,844 controls) participating in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. In bivariate regression spline models, exposures to cigarette smoking intensity and duration (compared with never smokers) were modeled as a linear piecewise function within a logistic regression also including potential confounders. We jointly estimated the optimal knot locations and regression parameters within the Bayesian framework. Results: For oral-cavity/pharyngeal (OCP) cancers, an odds ratio (OR) >5 was reached after 30 years in current smokers of ∼20 or more cigarettes/day. Patterns of OCP cancer risk in current smokers differed across strata of alcohol intensity. For laryngeal cancer, ORs >20 were found for current smokers of ≥20 cigarettes/day for ≥30 years. In former smokers who quit ≥10 years ago, the ORs were approximately halved for OCP cancers, and ∼1/3 for laryngeal cancer, as compared to the same levels of intensity and duration in current smokers. Conclusion: Referring to bivariate spline models, this study better quantified the joint effect of intensity and duration of cigarette smoking on HNC risk, further stressing the need of smoking cessation policies.

Published
2019

37. Nivolumab (Nivo) vs Investigator‘s Choice (IC) for Platinum-Refractory (PR) Recrrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CheckMate 141) : Outcomes in First-line (1L) R/M Patients (Pts) and Updated Safety and Efficacy

Author

Kasper, Stefan, Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Vokes, Everett E., Even, C., Worden, F., Saba, N. F., Docampo, L. C. I., Haddad, R., Rordorf, T., Kiyota, N., Makoto, T., Lynch, M., Kopit, J., and Ferris, R. L.

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2018

38. NRG-RTOG 1016: Phase III Trial Comparing Radiation/Cetuximab to Radiation/Cisplatin in HPV-related Cancer of the Oropharynx

Author

Trotti, A., primary, Harris, J., additional, Gillison, M., additional, Eisbruch, A., additional, Harari, P.M., additional, Adelstein, D.J., additional, Sturgis, E.M., additional, Galvin, J.M., additional, Koyfman, S., additional, Blakaj, D., additional, Razaq, M.A., additional, Colevas, A.D., additional, Beitler, J.J., additional, Jones, C.U., additional, Dunlap, N.E., additional, Seaward, S.A., additional, Spencer, S.A., additional, Ridge, J.A., additional, Phan, J., additional, and Le, Q.T., additional

Published
2018
Full Text
View/download PDF

39. Nivolumab Versus Investigator'S Choice (IC) for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CHECKMATE 141) : Outcomes in First-Line R/M Patients and Updated Safety and Efficacy

Author

Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, LCI, Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Lynch, M., Kopit, J., and Ferris, R. L.

Subjects
Medizin
Published
2017

40. Olfactory neuroblastoma

Author

Bell, D., Franchi, A., Gillison, M., Thompson, L. D. R., and Wenig, B. M.

Published
2017

41. Letter to the editor

Author

Wyss, A. B., Hashibe, M., Lee, Y. -C. A., Chuang, S. -C., Muscat, J., Chen, C., Schwartz, S. M., Smith, E., Zhang, Z. -F., Morgenstern, H., Wei, Q., Li, G., Kelsey, K. T., Winn, D. M., Gillison, M. L., Zevallos, J. P., Boffetta, P., Olshan, A. F., and Wyss, A.B. and Hashibe, M. and Lee, Y.-C.A. and Chuang, S.-C. and Muscat, J. and Chen, C. and Schwartz, S.M. and Smith, E. and Zhang, Z.-F. and Morgenstern, H. and Wei, Q. and Li, G. and Kelsey, K.T. and Winn, D.M. and Gillison, M.L. and Zevallos, J.P. and Boffetta, P. and Olshan, A.F.

Subjects
tobacco snuff, Letter, sex difference, disease association, prevalence, head and neck cancer, human, smokeless tobacco, cancer risk, smoking, United States, cancer epidemiology
Abstract

No abstract

Published
2017

42. Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups

Author

Ferris, R.L., primary, Blumenschein, G.R., additional, Fayette, J., additional, Guigay, J., additional, Colevas, A.D., additional, Licitra, L., additional, Harrington, K., additional, Kasper, S., additional, Vokes, E.E., additional, Even, C., additional, Worden, F., additional, Saba, N.F., additional, Docampo, LCIglesias, additional, Haddad, R.I., additional, Rordorf, T., additional, Kiyota, N., additional, Tahara, M., additional, Lynch, M., additional, Li, L., additional, and Gillison, M., additional

Published
2018
Full Text
View/download PDF

43. Neoadjuvant Pembrolizumab is Active in Surgically Resected Head and Neck Cancer

Author

Palackdharry, S., primary, Gillison, M., additional, Worden, F., additional, Old, M., additional, O'brien, P., additional, Dunlap, N.E., additional, Cohen, E., additional, Casper, K., additional, Mierzwa, M.L., additional, Morris, J.C., additional, Sadraei, N. Hashemi, additional, Huth, B., additional, Takiar, V., additional, Butler, R., additional, Mark, J., additional, Patil, Y., additional, Wilson, K., additional, Janssen, E., additional, Conforti, L., additional, Yaniv, B., additional, and Wise-Draper, T., additional

Published
2018
Full Text
View/download PDF

44. Safety Evaluation of Nivolumab Concomitant With Platinum-Based Chemoradiation therapy for Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504

Author

Gillison, M., primary, Ferris, R.L., additional, Zhang, Q., additional, Colevas, A.D., additional, Mell, L.K., additional, Kirsch, C., additional, Moore, K.L., additional, Truong, M.T., additional, Kong, C.S., additional, Jordan, R., additional, Clump, D.A., additional, Ohr, J., additional, He, K., additional, Blakaj, D., additional, Deeken, J., additional, Machtay, M., additional, Curran, W.J., additional, Harris, J., additional, and Le, Q.T., additional

Published
2018
Full Text
View/download PDF

46. 361O Patient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (Nivo) or Investigator’s Choice (IC): CheckMate 141

Author

Kiyota, N., primary, Harrington, K., additional, Ferris, R.L., additional, Shaw, J.W., additional, Taylor, F., additional, Derosa, M., additional, Turner-Bowker, D., additional, Morrissey, L., additional, Cocks, K., additional, Gillison, M., additional, and Guigay, J., additional

Published
2016
Full Text
View/download PDF

47. Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27 countries

Author

Conway, D.I. Brenner, D.R. McMahon, A.D. Macpherson, L.M.D. Agudo, A. Ahrens, W. Bosetti, C. Brenner, H. Castellsague, X. Chen, C. Curado, M.P. Curioni, O.A. Maso, L.D. Daudt, A.W. De Gois Filho, J.F. D'Souza, G. Edefonti, V. Fabianova, E. Fernandez, L. Franceschi, S. Gillison, M. Hayes, R.B. Healy, C.M. Herrero, R. Holcatova, I. Jayaprakash, V. Kelsey, K. Kjaerheim, K. Koifman, S. La Vecchia, C. Lagiou, P. Lazarus, P. Levi, F. Lissowska, J. Luce, D. Macfarlane, T.V. Mates, D. Matos, E. McClean, M. Menezes, A.M. Menvielle, G. Merletti, F. Morgenstern, H. Moysich, K. Müller, H. Muscat, J. Olshan, A.F. Purdue, M.P. Ramroth, H. Richiardi, L. Rudnai, P. Schantz, S. Schwartz, S.M. Shangina, O. Simonato, L. Smith, E. Stucker, I. Sturgis, E.M. Szeszenia-Dabrowska, N. Talamini, R. Thomson, P. Vaughan, T.L. Wei, Q. Winn, D.M. Wunsch-Filho, V. Yu, G.-P. Zhang, Z.-F. Zheng, T. Znaor, A. Boffetta, P. Chuang, S.-C. Ghodrat, M. Lee, Y.-C.A. Hashibe, M. Brennan, P.

Abstract

Low socioeconomic status has been reported to be associated with head and neck cancer risk. However, previous studies have been too small to examine the associations by cancer subsite, age, sex, global region and calendar time and to explain the association in terms of behavioral risk factors. Individual participant data of 23,964 cases with head and neck cancer and 31,954 controls from 31 studies in 27 countries pooled with random effects models. Overall, low education was associated with an increased risk of head and neck cancer (OR 5 2.50; 95% CI 5 2.02-3.09). Overall one-third of the increased risk was not explained by differences in the distribution of cigarette smoking and alcohol behaviors; and it remained elevated among never users of tobacco and nondrinkers (OR 5 1.61; 95% CI 5 1.13-2.31). More of the estimated education effect was not explained by cigarette smoking and alcohol behaviors: in women than in men, in older than younger groups, in the oropharynx than in other sites, in South/Central America than in Europe/North America and was strongest in countries with greater income inequality. Similar findings were observed for the estimated effect of low versus high household income. The lowest levels of income and educational attainment were associated with more than 2-fold increased risk of head and neck cancer, which is not entirely explained by differences in the distributions of behavioral risk factors for these cancers and which varies across cancer sites, sexes, countries and country income inequality levels. © 2014 UICC.

Published
2015

48. head and neck cancer Patient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (nivo) or investigator’s choice (IC): CheckMate 141

Author

Harrington, K., primary, Ferris, R.L., additional, Shaw, J., additional, Taylor, F., additional, Derosa, M., additional, Turner-Bowker, D., additional, Morrissey, L., additional, Cocks, K., additional, Kiyota, N., additional, Gillison, M., additional, and Guigay, J., additional

Published
2016
Full Text
View/download PDF

49. Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714

Author

Haddad, R., primary, Gillison, M., additional, Ferris, R.L., additional, Harrington, K., additional, Monga, M., additional, Baudelet, C., additional, Geese, W.J., additional, and Argiris, A., additional

Published
2016
Full Text
View/download PDF

50. A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

Author

Argiris, A., primary, Gillison, M., additional, Ferris, R.L., additional, Harrington, K., additional, Sanchez, T.K., additional, Baudelet, C., additional, Geese, W.J., additional, Shaw, J., additional, and Haddad, R., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results